Vera’s TRUTAKNA Gets FDA Nod with 42% UPCR Reduction, Awaits Kidney Data

The U.S. Food and Drug Administration granted accelerated approval to Vera Therapeutics’ TRUTAKNA (atacicept-vymj) for adults with primary IgA nephropathy (IgAN) at risk of disease progression. The approval marks a significant milestone as TRUTAKNA becomes the first and only inhibitor targeting both BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand), the two upstream cytokines that drive B-cell activation and subsequent production of galactose-deficient IgA1 (Gd-IgA1) immune complexes that damage the kidneys. This dual blockade directly addresses what Vera executives call the “key upstream drivers” of IgAN pathophysiology, a departure from existing therapies that either suppress inflammation broadly (corticosteroids) or target downstream complement activation (Novartis’s Fabhalta) or gut mucosal B cells (Calliditas’s Tarpeyo). The accelerated approval is based on the prespecified 36-week interim analysis of the ongoing, randomized, double-blind, placebo-controlled Phase 3 ORIGIN 3 trial (N=203 dosed). Patients receiving TRUTAKNA achieved a 46% reduction in 24-hour urine protein-to-creatinine ratio (UPCR) from baseline and a statistically significant 42% reduction compared with placebo. The proteinuria reduction was consistent across all prespecified subgroups, including age, sex, race, baseline eGFR, and concomitant SGLT2 inhibitor use. Additionally, TRUTAKNA treatment led to a 68% reduction in Gd-IgA1, the pathogenic autoantibody hallmark of IgAN, and resolution of hematuria—a key clinical sign—in a notable proportion of patients. Safety data, while not detailed in the release, are consistent with the known profile of atacicept, which has been studied in autoimmune diseases; common adverse events may include infections and injection-site reactions. The approval triggers a confirmatory post-marketing requirement to demonstrate benefit on kidney function, likely assessed by eGFR slope, which is the established endpoint for full approval in IgAN following the precedent set by Tarpeyo (budesonide) and other accelerated approvals in the space. Vera Therapeutics, trading under NASDAQ:VERA, has not disclosed a specific launch date, but the company says launch preparations are underway. The commercial opportunity in IgA nephropathy is substantial: the disease affects up to 150,000 people in the U.S., with many progressing to end-stage renal disease despite current therapies. In the broader context, the IgAN market has become highly competitive and innovation-rich. Calliditas’ Tarpeyo received full approval in December 2025, Novartis’ Fabhalta (iptacopan) won accelerated approval in August 2025, and others like Roche’s Zigakibart and Vera’s own earlier programs are advancing. TRUTAKNA’s first-in-class dual BAFF/APRIL mechanism may offer differentiation if it demonstrates superior efficacy and a convenient subcutaneous injection schedule. However, the pending confirmatory endpoint weighs on the investment thesis; the surrogate endpoint of proteinuria reduction has historically been accepted by the FDA, but the durability of kidney function preservation will ultimately dictate commercial success and reimbursement coverage. Looking ahead, the approval could catalyze a shift toward targeting upstream B-cell pathways in other glomerular diseases. Vera may pursue label expansion into lupus nephritis or other autoimmune kidney conditions where BAFF/APRIL play a role. Investors will closely watch the ORIGIN 3 confirmatory results and initial launch uptake metrics, as the company transforms from a clinical-stage to a commercial-stage biotech.